Erosive lichen planus: dramatic response to thalidomide

Dereure, O.

doi:10.1001/archderm.132.11.1392

Cited by 14 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…27,30 However, others have reported systemic absorption via oral mucosa or ingestion. 13 According to Hodgson et al, 26 in such cases, the possibility of contributing therapeutic systemic effect cannot be excluded.…”

Section: Post-treatment (5 Weeks)mentioning

confidence: 99%

“…12 Drugs used systemically are thalidomide, metronidazole, griseofulvin, hydroxychloroquine, some retinoids, and corticosteroids. 10,12,13 Recent reviews on OLP therapy suggest high-potency topical corticosteroids as the treatment of choice, and recommend clobetasol propionate to be the most effective topical steroid. 14,15 Nevertheless, refractory lesions to steroids require alternative medications.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of topical tacrolimus and clobetasol in the management of symptomatic oral lichen planus: A double‐blinded, randomized clinical trial in Sri Lanka

Hettiarachchi

Jayasinghe

et al. 2016

J of Invest & Clin Dent

View full text Add to dashboard Cite

show abstract

Section: Post-treatment (5 Weeks)mentioning

confidence: 99%

mentioning

confidence: 99%

Comparison of topical tacrolimus and clobetasol in the management of symptomatic oral lichen planus: A double‐blinded, randomized clinical trial in Sri Lanka

Hettiarachchi

Jayasinghe

et al. 2016

J of Invest & Clin Dent

View full text Add to dashboard Cite

show abstract

“…A patient with generalized lichen planus refractory to multiple drugs was given thalidomide 300 mg daily for 2 weeks and then 200 mg daily for another 10 weeks, which resulted in resolution of all his lesions 74 . Four patients with refractory oral lichen planus were successfully treated with thalidomide 25–150 mg daily for 15–36 months without recurrence or adverse effects 56,75 , 76 . A patient with erosive flexural lichen planus was successfully treated with a combination of thalidomide and tacrolimus 0·1% ointment 77 …”

Section: Possibly Effectivementioning

confidence: 99%

Thalidomide: dermatological indications, mechanisms of action and side-effects

et al. 2005

View full text Add to dashboard Cite

Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects. However, it has since made a remarkable comeback for the U.S. Food and Drug Administration-approved use in the treatment of erythema nodosum leprosum. Further, it has shown its effectiveness in unresponsive dermatological conditions such as actinic prurigo, adult Langerhans cell histiocytosis, aphthous stomatitis, Behçet's syndrome, graft-versus-host disease, cutaneous sarcoidosis, erythema multiforme, Jessner-Kanof lymphocytic infiltration of the skin, Kaposi sarcoma, lichen planus, lupus erythematosus, melanoma, prurigo nodularis, pyoderma gangrenosum and uraemic pruritus. This article reviews the history, pharmacology, mechanism of action, clinical uses and adverse effects of thalidomide.

show abstract

“…A recent small trial involving OLP patients with chronic HCV infection suggests than glycyrrhizin (an active component of liquorice roots) may also be useful in treating OLP (Nagao et al, 1996b). Phenytoin (Bogaert and Sanchez, 1990), thalidomide (Dereure et al, 1996), diethyldithiocarbamate (Sun et al, 1991), eiconol (Barer and Polovets, 1995) and enoxaparin (Hodak et al, 1998) are other uncommon agents used in the treatment of OLP, but their value, like that of surgical excision, cryosurgery, laser surgery (Emslie and Hardman, 1970;Frame et al, 1984;Horsh and Gerlach, 1986), psychotherapy (Hampf et al, 1987;McCartan, 1995), magnetism (Kupriianova et al, 1989) and reflexotherapy (Maksimovskaia et al, 1991) remains to be established.…”

Section: Other Treatmentsmentioning

confidence: 99%

The management of oral lichen planus

1999

View full text Add to dashboard Cite

OBJECTIVE: To review the current literature regarding the medical treatment of oral lichen planus (OLP). DATA SOURCES: PubMed on‐line Medline data searches were carried out for the years 1966–1998 to identify reports on therapy of OLP. METHODS OF STUDY SELECTION: Single case reports or open trials were included if they covered new therapeutic approaches or suggested significant modifications of known treatment modalities. Review papers were limited to those dealing with the topic. DATA EXTRACTION AND SYNTHESIS: Every paper was critically examined. Because of the great heterogeneity of the response criteria, many data could not be directly compared. Stronger weight was given to therapies that have proven to be effective under placebo‐controlled research protocols. Attention was also drawn to potential and effective adverse effects of every drug used. CONCLUSIONS: Among the various medications advocated for the treatment of OLP, several lack conclusive findings from adequately controlled trials. Mainly high‐potency topical corticosteroids in an adhesive medium appear at present the safest and most efficacious. Adjuvant agents as antimycotics may be useful in topical steroid treatment. Systemic corticosteroids may be occasionally indicated for severe recalcitrant erosive OLP or for diffuse mucocutaneous involvement. Topical cyclo‐sporine should be considered in steroid‐unresponsive cases considering that its efficacy in OLP could be related to a systemic effect and its high cost. Classical PUVA therapy seems to have too many side effects; topical application of psoralen is promising but still experimental. Topically and systemically delivered retinoids combined with topical corticosteroids could improve the efficacy of these agents whereas complete remission is difficult to achieve with retinoids alone and they frequently cause adverse effects. Finally, there are only few data concerning the long‐term effect of the medical treatments upon the course of OLP and we do not know if therapy influences the malignant evolution of OLP.

show abstract

Erosive lichen planus: dramatic response to thalidomide

Cited by 14 publications

References 0 publications

Comparison of topical tacrolimus and clobetasol in the management of symptomatic oral lichen planus: A double‐blinded, randomized clinical trial in Sri Lanka

Comparison of topical tacrolimus and clobetasol in the management of symptomatic oral lichen planus: A double‐blinded, randomized clinical trial in Sri Lanka

Thalidomide: dermatological indications, mechanisms of action and side-effects

The management of oral lichen planus

Contact Info

Product

Resources

About